Duo package Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be featured on “Give Gorgeous - Gifts With Purchase” on November 19 at 4 p.m. Eastern time
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network. Dr. Kunin will discuss DERMAdoctor’s moisturizing Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on “Give Gorgeous – Gifts With Purchase” hosted by two of QVC’s most popular hosts, Jennifer Coffey and Terri Conn, on Saturday, November 19 at 4 p.m. Eastern time.
“I am excited to share our moisture-rich, problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on QVC just in time for holiday giving,” said Dr. Kunin. “Dry indoor air during the winter months can exacerbate parched, eczema-prone skin, leading to itching, redness and discomfort. Our nourishing balm maximizes hydration to calm irritated skin with a special formulation of colloidal oatmeal combined with time-honored, beloved dermatologic botanicals, and is gentle enough to be used head to toe. Like all DERMAdoctor products, it is formulated with a mixture of compassion and expertise.”
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm was recently selected as among the top 2022 picks for best eczema lotions by two medically reviewed online publications: Medical News Today as the best full body lotion and Verywell Health as the best calming lotion. Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm incorporates a special form of eczema-active 1% colloidal oatmeal with enhanced beta glucan, an advanced complex of ceramides and essential lipids, along with dermatologic botanicals including evening primrose, black currant and borage seed oils and linoleic acid.
Dr. Kunin is a board-certified dermatologist, author, clinician, educator, television personality and recognized trailblazer in the skincare industry. DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns that have been overlooked by the beauty industry. DERMAdoctor delivers on the promise that clinical skin therapy can be simple and easy.
Eczema affects an estimated 31 million Americans, according to the Asthma and Allergy Foundation of America. Atopic dermatitis, the most common form of eczema, is a chronic, inflammatory skin disease that results in widespread rashes and patches of itchy skin. Those afflicted report limitations that impact their daily activities and cause them to avoid social interactions.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the integration of DERMAdoctor’s business into the Company’s business, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.